What Is Lixisenatide? Everything You Should Know Before Starting

Lixisenatide at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Sanofi
• FDA approved: 2016
• Route: subcutaneous injection
• Typical frequency: once daily before the first meal
• Half-life: approximately 3 hours
• Cash price (US): $700-$850/month without insurance
• Receptor target: GLP-1 receptor

Lixisenatide has become one of the more talked-about names in the glp-1 receptor agonist space. The clinical reality is more nuanced than the headlines suggest, and most of what matters fits in a few sentences. Lixisenatide is a short-acting GLP-1 receptor agonist with prominent effects on postprandial glucose.

What is Lixisenatide?

Lixisenatide is a short-acting GLP-1 receptor agonist with prominent effects on postprandial glucose. Its short half-life produces strong gastric-emptying delay after meals.

Lixisenatide is manufactured by Sanofi. Lixisenatide was approved by the FDA in 2016. Its approved indications include type 2 diabetes. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. Here's how that breaks down.

How Lixisenatide Works in the Body

Lixisenatide is a short-acting GLP-1 receptor agonist with prominent effects on postprandial glucose. Its short half-life produces strong gastric-emptying delay after meals. The receptor target — GLP-1 receptor — drives the downstream effects users care about: a1c reductions of 0.5-0.9% with modest weight loss (~1-2 kg). strong postprandial glucose effect.

The pharmacokinetics matter for daily use. Lixisenatide has a half-life of approximately 3 hours, which determines how often it is dosed. The standard route of administration is subcutaneous injection, and the typical schedule is once daily before the first meal.

For more detail on the underlying biology, see our breakdown of how Lixisenatide works.

Who Uses Lixisenatide?

Lixisenatide is most relevant for people whose situation maps to its approved indications: type 2 diabetes.

People who should avoid Lixisenatide include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome

Common and Serious Side Effects

The most commonly reported side effects of Lixisenatide include:

• nausea
• vomiting
• headache
• diarrhea

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• severe hypersensitivity reactions

We have a more detailed breakdown in our Lixisenatide side-effects guide.

Lixisenatide vs Alternatives

Most clinicians now favor longer-acting GLP-1 agonists like semaglutide or dulaglutide over lixisenatide for both efficacy and dosing convenience. If you are weighing Lixisenatide against another option, our comparison pages include Liraglutide Explained: How It Works and Who It's For, Dulaglutide Explained: How It Works and Who It's For, Liraglutide Side Effects: The Complete List and How to Handle Them.

Bottom Line

Lixisenatide fits into a broader landscape of glp-1 receptor agonist options. The right choice for any individual depends on insurance, side-effect tolerance, dosing preference, and prescriber familiarity — usually more than on the molecule itself. Multiple randomized controlled trials support its efficacy. If you are considering Lixisenatide, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Liraglutide Explained: How It Works and Who It's For
• Dulaglutide Explained: How It Works and Who It's For
• Liraglutide Side Effects: The Complete List and How to Handle Them
• Real Liraglutide Results: What 6 and 12 Months Actually Look Like
• What Is Exenatide? Everything You Should Know Before Starting
• The Real Liraglutide Price Tag in 2026 — With and Without Insurance

Sources

• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.
• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.